Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
The FDA has lifted the clinical hold on Filana Therapeutics' investigational new drug application for simufilam, clearing the company to proceed with a planned Phase 2a proof-of-concept study in TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027. The 16-week multicenter, randomized, double-blind trial will run at 13 U.S. sites with a target enrollment of 40 subjects aged 12 to 55, and completers are eligible for a 48-week extension study.
Key figures
- Drug Name
- simufilam
- Phase Of Trial
- Phase 2a
- Trial sites
- 13
- Subject age range
- 12 to 55
- Target enrollment
- 40
- Trial duration weeks
- 16
- Extension study weeks
- 48
- Patient screening start
- Q1 2027
- Us tsc epilepsy population
- 45000
- Tsc patients refractory to therapy
- >60%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.